NYSE$OSCR
Oscar Health Inc · Q4 2025 earnings
Q4 2025 earnings · · Before market open · Investor relations
Briefing
Oscar Health reported Q4 2025 total revenue of $2.81B with a net loss of $352.6M.
Total revenue rose to $2.81 billion on higher membership. The company posted a net loss of $352.6 million as medical costs and risk adjustment transfers weighed on profitability.
- Q4 revenue $2.81B.
- Membership growth drove top line.
- Net loss $(352.6)M in the quarter.
- Medical cost trends key to 2026 margins.
Headline financials
Revenue & EPS history
Oscar Health · Revenue · Quarterly
$2.81B
Forward guidance
The release discusses Oscar Health's outlook, including operating priorities, capital returns, and sector risks relevant to upcoming periods.
Tailwinds
- Oscar Health cites execution on strategic priorities and demand trends in the release.
- Capital allocation and balance-sheet actions support growth and shareholder returns.
Headwinds
- GAAP profitability remained under pressure in Q4 2025.
- Macro, pricing, and input-cost volatility could pressure margins.
- One-time items and segment mix may affect quarter-to-quarter comparability.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2025
+3.7%
Avg return
Earnings day
+5.6%
Avg return
5 days after
+7.5%
Avg return
30 days after
64%
16 / 25 earnings
Positive
+30.0%
Q1 2025
Best reaction
-23.9%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.7% | +22.6% | +36.6% | |
| Q4 2025 | +1.7% | +6.0% | +2.7% | |
| Q3 2025 | -2.8% | -12.8% | -1.5% | |
| Q1 2025 | +30.0% | +28.7% | +18.0% | |
| Q4 2024 | +3.1% | -3.7% | +4.5% | |
| Q3 2024 | -12.9% | -12.8% | +0.4% | |
| Q2 2024 | +7.2% | +4.4% | -1.4% | |
| Q1 2024 | +9.3% | +14.1% | +2.8% | |
| Q4 2023 | +22.7% | +27.5% | +7.7% | |
| Q3 2023 | +23.5% | +24.5% | +42.0% | |
| Q2 2023 | +8.6% | +1.9% | -10.5% | |
| Q1 2023 | -8.8% | -6.6% | +17.8% | |
| Q4 2022 | +21.0% | +36.2% | -3.9% | |
| Q3 2022 | -23.9% | -4.5% | -11.3% | |
| Q2 2022 | +19.9% | +21.1% | -3.7% | |
| Q1 2022 | -8.9% | -2.0% | -25.0% | |
| Q4 2019 | +6.3% | +2.5% | +39.1% | |
| Q4 2021 | +2.4% | +15.6% | +21.9% | |
| Q3 2020 | -2.4% | -6.3% | -12.7% | |
| Q3 2021 | -23.3% | -25.2% | -33.0% | |
| Q2 2020 | -16.4% | -11.8% | +19.4% | |
| Q2 2021 | -0.9% | -12.0% | +17.9% | |
| Q4 2020 | +15.2% | +14.5% | +23.1% | |
| Q1 2020 | +15.2% | +14.5% | +23.1% | |
| Q1 2021 | +3.6% | +4.2% | +14.0% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro